Research Studies
A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants with head and neck squamous cell carcinoma (HNSCC)
Details
Age
Adult
Eligibility
INCLUSION: - Histologically or cytologically confirmed diagnosis of R/M HNSCC that is considered not amenable to further therapy with curative intent. The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx (nasopharynx is excluded). - Known HPV p16 status for oropharyngeal cancer. EXCLUSION: - Has received prior IL2-based anti-cancer treatment.
Type of Study
Treatment
Locations
University of Colorado Hospital
Principal Investigator
Antonio Jimeno, MD, PhD
Study ID
Protocol Number: 21-4146
More information available at ClinicalTrials.gov: NCT05061420
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers